Akrivis Technologies, LLC is a privately held biotech company committed to the early detection, diagnosis and treatment of life-threatening diseases. The company is focused on the development of its patented Z-TECT� signal amplification and therapeutic technology platform. Akrivis currently offers its first generic ultrasensitive reagents as well as its "Antibody Rescue Services", which modify a client's primary antibodies into custom-made ultrasensitive immunoassay reagents.